Compare BSRR & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSRR | AURA |
|---|---|---|
| Founded | 1977 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.8M | 396.8M |
| IPO Year | 1994 | 2021 |
| Metric | BSRR | AURA |
|---|---|---|
| Price | $32.16 | $6.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $34.50 | $20.33 |
| AVG Volume (30 Days) | 40.0K | ★ 197.8K |
| Earning Date | 10-27-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | ★ 14.51 | N/A |
| EPS | ★ 2.88 | N/A |
| Revenue | ★ $144,486,000.00 | N/A |
| Revenue This Year | $8.70 | N/A |
| Revenue Next Year | $3.92 | N/A |
| P/E Ratio | $11.24 | ★ N/A |
| Revenue Growth | ★ 0.56 | N/A |
| 52 Week Low | $22.42 | $4.35 |
| 52 Week High | $32.82 | $9.14 |
| Indicator | BSRR | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 67.57 | 60.80 |
| Support Level | $31.09 | $5.89 |
| Resistance Level | $32.82 | $6.53 |
| Average True Range (ATR) | 0.80 | 0.33 |
| MACD | 0.24 | 0.10 |
| Stochastic Oscillator | 85.78 | 86.21 |
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.